J&J Expands Ketamine Case With Spravato Monotherapy Indication

 
• By Joseph Haas
  
J&J obtained a third US indication for treatment-resistant depression drug Spravato • Source: Scrip
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Business

More from Therapy Areas